An Introduction to Stroke
The majority of strokes (85%) are caused by acute ischaemia resulting from the blockage of a cerebral artery, leading to a loss of oxygenation in downstream brain tissue, and ultimately causing neuronal cell death and irreversible neurological damage. The remainder are haemorrhagic strokes, caused by intracerebral haemorrhage or subarachnoid haemorrhage. The treatment of ischaemic stroke has been transformed by advances in imaging technology, as well as the emergence of thrombolytic therapy and subsequent mechanical thrombectomy, sometimes facilitating complete recovery. The increasing use of direct oral anticoagulants is preventing stroke in patients with atrial fibrillation. Therapies targeting neuroinflammation after brain ischaemia, such as transplantation of mesenchymal stem cells, are also emerging as a potentially useful treatment option.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Addressing cardiorenal outcomes in CKD and T2D: What are the key considerations for daily practice?
Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D
- Identify the epidemiological and pathophysiological drivers behind the progression of CKD
- Recognize the specific renal and cardiovascular risks associated with CKD and T2D and the therapies available to address them
- Apply the latest clinical guidelines to treating patients with CKD and T2D in daily practice
Steven Messe, TCT 2022: Sentinel® cerebral protection system efficacy in reducing all stroke/disabling stroke, the PROTECTED-TAVR trial (a neurologist’s perspective)
The PROTECTED-TAVR trial studied the efficacy of using an embolic protection device (Sentinel® cerebral protection system) during transcatheter aortic valve replacement in reducing the incidence of stroke/disabling stroke. In this touchCARDIO interview, we speak with Dr Steven Messe (University of Pennsylvania, Philadelphia, PA, USA) to give a Neurologist’s perspective on the findings of the PROTECTED-TAVR […]
The Hype Surrounding Patent Foramen Ovale Closure and Cryptogenic Stroke: A Walk Through History
Heart International. 2022;16(1):59–63 DOI: https://doi.org/10.17925/HI.2022.16.1.59
Cryptogenic stroke (CS) is a brain infarction that cannot be clearly attributed to cardioembolism, large-vessel atherosclerosis or small artery disease, despite extensive clinical evaluation.1 It represents approximately one-third of all ischaemic strokes worldwide.2 Stroke represents a major public health crisis, as it is the fifth most common cause of death in the USA and a significant cause […]
Patent Foramen Ovale Closure—Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke
US Neurology. 2020;16(1):54–60
Globally, a high proportion (around 25%) of transient ischemic attacks (TIAs) and ischemic strokes are cryptogenic.1,2 The Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification defines a cryptogenic stroke as a brain infarction that is not caused by definite cardioembolism, large artery atherosclerosis, or small artery disease, despite extensive investigations.3 The “ASCOD” classification defines strokes […]
Andexanet Alfa and its Clinical Application
Heart International. 2020;14(1):20-3 DOI: https://doi.org/10.17925/HI.2020.14.1.20
The factor Xa (FXa) inhibitors apixaban, rivaroxaban and edoxaban, together with the thrombin inhibitor dabigatran, are collectively referred to as non-vitamin K antagonist (or direct) oral anticoagulants (NOACs). FXa inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation,1 and for the treatment and prevention of deep vein thrombosis and pulmonary embolism.2,3 In patients […]
Atrial Fibrillation and Dementia
European Journal of Arrhythmia & Electrophysiology. 2020;6(1):10-6 DOI: https://doi.org/10.17925/EJAE.2020.6.1.10
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1 AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF during their lifetime.2,3 Irrespective of age, AF incidence also increases with diabetes […]
Full Annual Costs of Stroke in 32 European Countries is €60 Billion
In 2017, nearly 1.5 million people suffered a stroke, nine million Europeans lived with a stroke, and more than 430,000 people died due to a stroke in the 32 countries, based on findings from a new study.1 The total annual costs for stroke were over €60 billion, a figure revealed by the Economic Impact […]
Aldo Pietro Maggioni, ESC 2019 – Oral Anticoagulants and Ischaemic Stroke in Atrial Fibrillation
We spoke to Dr Aldo Pietro Maggioni (Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Research Center, Florence, Italy) about the key observations from his study of trends in oral anticoagulant use and the rate of ischaemic stroke in people with atrial fibrillation. He also discussed how big data can provide insight and what he expects to […]
Novel Oral Anticoagulants – Do Real-world Data Support our Expectations?
European Journal of Arrhythmia & Electrophysiology. 2019;5(1):48-58 DOI: https://doi.org/10.17925/EJAE.2019.5.1.48
Atrial fibrillation (AF) is one of the most common cardiac diseases in elderly patients and is associated with increased morbidity and mortality. It is of great importance to treat patients with AF with oral anticoagulants (OACs) to prevent ischaemic strokes, which represents the most relevant complication of AF. For many decades, vitamin K antagonists (VKAs) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!